Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2024 04:00 ET | Source: Laverock Therapeutics

Laverock Therapeutics to Present New Data on Programmable, Tunable, Stable and Specific Gene Silencing Platform at ESGCT

STEVENAGE, United Kingdom, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced...
October 22, 2024 02:00 ET | Source: Epicrispr Biotechnologies

Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Epicrispr Biotechnologies, a leading epigenetic editing company, presented new data on its hypercompact platform for epigenetic...
October 22, 2024 02:00 ET | Source: Ring Therapeutics

Ring Therapeutics Presents Preclinical Data on Anellogy™ Platform at the 31st Annual European Society of Gene & Cell Therapy Conference

- Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirus CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ring...
October 22, 2024 01:00 ET | Source: BioVersys

BioVersys Joins EU-Funded RespiriNTM Programme to Accelerate Development of Its Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases

BASEL, Switzerland, Oct. 22, 2024 (GLOBE NEWSWIRE) -- RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive fundingBioVersys taps into key expertise of the...
October 22, 2024 00:30 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
October 21, 2024 22:11 ET | Source: King Faisal Specialist Hospital & Research Centre

KFSHRC lanza unidad móvil de accidente cerebrovascular para acelerar el tratamiento del paciente

RIAD, Arabia Saudita, Oct. 21, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) lanzó la primera Unidad de Ambulancia Móvil para Accidentes Cerebrovasculares...
October 21, 2024 22:11 ET | Source: King Faisal Specialist Hospital & Research Centre

KFSHRC Lança Unidade Móvel de AVC para Acelerar Tratamento do Paciente

RIADE, Arábia Saudita, Oct. 21, 2024 (GLOBE NEWSWIRE) -- O King Faisal Specialist Hospital & Research Centre (KFSH&RC) lançou a primeira Unidade Móvel de Ambulância para AVC do...
October 21, 2024 22:11 ET | Source: King Faisal Specialist Hospital & Research Centre

KFSHRC startet mobile Schlaganfallstation für schnellere Patientenbehandlung

RIYADH, Saudi-Arabien, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Das King Faisal Specialist Hospital & Research Centre (KFSHRC) hat die erste mobile Schlaganfallstation im Mittleren Osten und in...
October 21, 2024 22:11 ET | Source: King Faisal Specialist Hospital & Research Centre

Le KFSHRC lance une unité mobile de traitement des accidents vasculaires cérébraux pour accélérer la prise en charge des patients

RIYAD, Arabie Saoudite, 22 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSHRC) a lancé la première unité mobile de soins ambulatoires pour les accidents...
October 21, 2024 20:00 ET | Source: Annexon Biosciences

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER...